Sorrento Therapeutics, Inc.
SRNEDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Abivertinib
Covid-19
STI-5656
Covid19
COVI-DROPS
Covid19
STI-6129
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Abivertinib | Phase 2 | Covid-19 | - | - |
STI-5656 | Phase 2 | Covid19 | - | - |
COVI-DROPS | Phase 2 | Covid19 | - | - |
STI-6129 | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in Sorrento Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Sorrento Therapeutics, Inc.'s (SRNE) pipeline across Phase 2. Its lead program is Abivertinib (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sorrento Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Sorrento Therapeutics, Inc. (SRNE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SRNE biotech catalysts?→
Add SRNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sorrento Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.